![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 28, 25152-25159, July 12, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§,
,
,
,
,
,
,
¶, and
¶
From the
Department of Pharmacology and the
¶ Neurosciences and Biomedical Sciences Programs, School of
Medicine, University of California at San Diego, La Jolla, California
92093-0636 and the § Department of Molecular Genetics,
National Institute of Neuroscience, National Center of Neurology
and Psychiatry (NCNP), Ogawahigashi 4-1-1, Kodaira,
Tokyo 187-8502, Japan
Received for publication, January 7, 2002, and in revised form, April 30, 2002
| |
ABSTRACT |
|---|
|
|
|---|
Five cognate G protein-coupled receptors
(S1P1-5) have been shown to mediate various cellular
effects of sphingosine 1-phosphate (S1P). Here we report the generation
of mice null for S1P2 and for both S1P2 and
S1P3. S1P2-null mice were viable and fertile
and developed normally. The litter sizes from
S1P2S1P3 double-null crosses were remarkably
reduced compared with controls, and double-null pups often did not
survive through infancy, although double-null survivors lacked any
obvious phenotype. Mouse embryonic fibroblasts (MEFs) were examined for
the effects of receptor deletions on S1P signaling pathways. Wild-type
MEFs were responsive to S1P in activation of Rho and phospholipase C
(PLC), intracellular calcium mobilization, and inhibition of
forskolin-activated adenylyl cyclase. S1P2-null MEFs showed
a significant decrease in Rho activation, but no effect on PLC
activation, calcium mobilization, or adenylyl cyclase inhibition.
Double-null MEFs displayed a complete loss of Rho activation and a
significant decrease in PLC activation and calcium mobilization, with
no effect on adenylyl cyclase inhibition. These data extend our
previous findings on S1P3-null mice and indicate
preferential coupling of the S1P2 and S1P3
receptors to Rho and PLC/Ca2+ pathways, respectively.
Although either receptor subtype supports embryonic development,
deletion of both produces marked perinatal lethality, demonstrating an
essential role for combined S1P signaling by these receptors.
Sphingosine 1-phosphate
(S1P)1 is a bioactive
lysophospholipid that elicits diverse physiological effects on most
types of cells and tissues. Several lines of evidence from a wealth of in vitro studies revealed that these effects are induced by
S1P activation of any of five cognate G protein-coupled receptors: S1P1 (LPB1/EDG-1), S1P2
(LPB2/H218/AGR16/EDG-5), S1P3
(LPB3/EDG-3), S1P4 (LPC1/EDG-6),
and S1P5 (LPB4/NRG-1/EDG-8) (reviewed in Refs. 1-7). In part reflecting a lack of receptor subtype-specific agonists/antagonists and the universal expression of multiple S1P
receptor genes in many single cell types, the in vivo roles of each receptor were unclear until the recent use of
genetic approaches in mice (reviewed in Ref. 44).
Liu et al. (8) reported that S1P1-null mice
are lethal. S1P1-null mice exhibit embryonic
hemorrhage and incomplete vascular maturation, which lead to
intrauterine death. S1P-induced cell migration and activation of the
small GTPase Rac are severely defective in S1P1-null mouse
embryonic fibroblasts (MEFs), suggesting that the loss of S1P cellular
signaling is relevant to those phenotypes found in
S1P1-null mice (8). We observed that S1P3-null
mice are without marked phenotypic differences compared with controls (9). However, S1P-induced phospholipase C (PLC) activation is severely
defective in S1P3-null MEFs (9). In this study, we
generated S1P2-null mice. S1P2-null mice were
viable and apparently normal, as were S1P3-null mice.
However, S1P-induced Rho activation was impaired. By contrast, PLC
activation, intracellular calcium mobilization, and adenylyl cyclase
inhibition were normal in S1P2-null MEFs.
To determine whether the S1P2 and S1P3
receptors serve redundant functions, we further generated mice null for
these two receptor subtypes, S1P2S1P3
double-null mice. A remarkable in vivo phenotype was found
in double-null mice: markedly decreased litter sizes from double-null
crosses. In addition, in vitro analysis of receptor function
demonstrated that S1P-induced activation of Rho and PLC and
intracellular calcium mobilization, but not adenylyl cyclase inhibition, were severely defective in double-null MEFs. These results
identify a new physiological function for S1P receptor signaling and
perinatal survival and indicate non-redundant signaling roles for these
individual lysophospholipid receptors.
Materials--
[ Generation of s1p2 Mutant Mice--
The isolation of
an s1p2 Care and Genotyping of Mice--
Mice were housed in an
air-conditioned room kept on a 12-h dark/light cycle and fed standard
dry rodent food pellets ad libitum. The
s1p2 genotyping was done by Southern blot analysis
and, more routinely, by PCR using tail genomic DNA and the following
three primer sets: primer 1, 5'-ACACCCTTTGTATCAAGTGGCAA-3'; primer 2, 5'-TTCTGGAGGGTAACACAGTGGT-3'; and primer 3, 5'-GCTAAAGCGCATGCTCCAGACT-3'. The PCR conditions were 35 cycles of
94 °C for 30 s, 56 °C for 1 min, and 72 °C for 1 min.
Northern Blot Analysis--
Mouse tissues were quickly removed
and homogenized in the Trizol reagent with the Tissue Tearor (Biospec
Products, Inc., Bartlesville, OK). Total RNA was isolated following the
instructions of Invitrogen, and 20 µg of each RNA was analyzed as
described previously (9, 13). Specific probes used were the ORF
sequences for the mouse lpa1,
s1p1-3, and s1p5 genes and
s1p4 cDNA (9).
Histological Analysis--
Histological analyses for
s1p2 phenotypes were done on the progenies on a
purer C57BL/6N background (backcrossed three to five generations;
N3-N5). The s1p2-heterozygous
(s1p2+/ Preparation of MEFs--
MEFs were prepared from embryonic day
14 embryos generated by the wild-type or knockout (single or double)
intercrosses as described previously (9). MEFs were maintained as a
monolayer culture on tissue culture dishes in Dulbecco's modified
Eagle's medium supplemented with 10% heat-inactivated fetal bovine
serum and antibiotics. Cells from the second to third passages were used for analyses.
Functional Assays in MEFs--
All functional assays except for
the intracellular calcium mobilization assay were carried out as
described previously (9). Briefly, for the PLC assay, MEFs on 12-well
dishes were prelabeled with [3H]inositol (2 µCi/well)
in inositol- and serum-free medium for 24 h and stimulated with
S1P or LPA in Hepes/Tyrode's/BSA buffer (14). After a 20-min
incubation, radioactivity in the inositol monophosphate + inositol bisphosphate + inositol trisphosphate fractions of the cell
extracts was examined as described previously (9, 13, 14). The activity
was expressed as a percentage of the 10 µM LPA-induced response.
For cAMP determination, MEFs on 24-well dishes were preincubated in
Hepes/Tyrode's/BSA buffer containing 0.5 mM
3-isobutyl-1-methylxanthine for 20 min and then stimulated for 20 min with or without 1 µM forskolin in the presence or
absence of S1P. cAMP contents were measured with the cAMP enzyme
immunoassay system (Amersham Biosciences) following the manufacturer's
instructions. The activity was expressed as percentages of basal levels
or 1 µM forskolin-induced cAMP accumulation.
For Rho and Rac assays (9), MEFs on 10-cm dishes were incubated for 10 min in Hepes/Tyrode's/BSA buffer and then stimulated for 3 min with
S1P or LPA. Cells were lysed and incubated with Rhotekin Rho-binding
domain- and PAK1 p21-binding domain-conjugated agarose beads,
respectively. GTP-bound active forms of Rho or Rac protein were
specifically detected by Western blot analysis using anti-RhoA (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) and anti-Rac1 (BD
PharMingen) antibodies, respectively. Rho protein in 5% of the
cell lysate and Rac protein in 1% of the cell lysate were also
detected as references, respectively.
For calcium mobilization assay, MEF cells were loaded with Fura 2/AM (1 µM) in Hepes/Tyrode's/BSA buffer for 1 h. The cells were successively stimulated with 10 µM S1P, 10 µM LPA, and 1 mM ATP in Hepes/Tyrode's/BSA
buffer containing 1.8 mM CaCl2. Measurements of
intracellular calcium concentration were performed using a Hitachi
F-2000 fluorescence spectrophotometer at excitation wavelengths of 340 and 380 nm and an emission wavelength of 510 nm. Conversion of the
340/380 nm ratio value into nanomolar intracellular Ca2+
was estimated by comparing the cellular fluorescence ratio with ratios
acquired with buffers containing known Ca2+ concentrations.
Data Representation--
Data are the means ± S.E. of
triplicate samples from a single experiment representative of two to
three experiments that gave similar results. Statistical analyses were
done by Student's t test or the Generation of S1P2-null Mice--
The genomic
structure of s1p2 consists of two exons, with the
entire ORF encoded in the second exon (12). Therefore, the entire ORF
was deleted in R1 embryonic stem cells by replacing it with a
neomycin-resistance gene (Fig.
1A). The correct integration of the targeting construct was confirmed by Southern blot analysis using probes both inside (Probe B) and outside (Probe
A) of the ORF (Fig. 1, A and B, left
panels). A single correctly targeted embryonic stem clone was
injected into blastocysts, and a series of mice with mutated
s1p2 alleles
(s1p2+/ No Obvious Phenotypic Abnormality in S1P2-null
Mice--
S1P2-null mice were generally obtained with the
expected mendelian frequency and without sexual bias (Table
I). S1P2-null mating produced
S1P2-null pups, although the average litter size was
modestly but significantly (p < 0.01) smaller than
that from s1p2+/
S1P2-null mice did not differ from the wild-type or
s1p2+/ Generation and Analysis of S1P2S1P3
Double-null Mice--
The viability and fertility of both
S1P2-null and S1P3-null mice (9) enabled the
generation of S1P2S1P3 double-null mice by
successive crossbreeding. First,
s1p2+/
S1P2S1P3 double-null mice from
s1p2+/ Expression of S1P Receptor Genes in MEF Cells--
To determine
the contribution of s1p2 (and/or
s1p3) deletion to S1P cellular signaling, we
analyzed MEF cells prepared from embryonic day 14 embryos. First,
expression of the s1p genes in each cell preparation was
examined by Northern blot analysis (Fig. 2). Consistent with our previous
observation (9), wild-type MEF cells expressed
s1p1-3, but neither s1p4 nor
s1p5. As expected, MEF cells from each of the
mutants lacked expression of their corresponding s1p
gene(s). There were no obvious compensatory changes in the expression
of other S1P receptor genes or an LPA receptor gene,
lpa1 (Fig. 2).
S1P-induced PLC Activation in MEF Cells--
S1P
concentration-dependent PLC activation was measured using
radioisotope labeling methods (see "Experimental Procedures"). MEF
cells express two LPA receptor genes (lpa1
and lpa2) and were responsive to LPA in both PLC and
Rho activation (13).2 The
responses to LPA stimulation were comparable among the MEF cell
types (4.3-6.0-fold induction above basal levels at 10 µM), and thus, S1P-induced responses were expressed as a
percentage of the 10 µM LPA-induced response.
As observed previously (9), wild-type MEF cells were highly responsive
to S1P in PLC activation, whereas S1P3-null cells showed
markedly diminished PLC activation in response to S1P (Fig. 3). Deletion of the S1P2
receptor did not affect this response because S1P-induced PLC
activation in S1P2-null cells was comparable to that in
wild-type cells, and that in S1P2S1P3
double-null cells was comparable to that in S1P3-null cells
(Fig. 3). These results indicate that the S1P2 receptor
does not mediate PLC activation in response to S1P in these cells. This
is consistent with our previous observation that
s1p2 overexpression does not affect S1P-induced PLC
activation in S1P3-null MEF cells (9).
S1P-induced Intracellular Calcium Mobilization in MEF
Cells--
S1P-induced intracellular calcium mobilization was measured
by Fura 2/AM labeling methods (see "Experimental Procedures"). Wild-type MEF cells were highly responsive to both S1P and LPA (Fig.
4A). Deletion of
S1P3, but not S1P2, in MEF cells resulted in no
or minimal response to S1P in calcium mobilization, whereas responses
to LPA or ATP were comparable among all MEF cell types (Fig. 4,
B-D). These results indicate that S1P3, but not
S1P2, plays a major role in S1P-induced intracellular
calcium mobilization.
S1P-induced Modulation of Adenylyl Cyclase Activity in MEF
Cells--
First, we compared the effects of S1P on forskolin-induced
cAMP accumulation in each of the mutant MEF cells. The
concentration-dependent inhibitory effects of S1P were
comparable among wild-type, S1P2-null, and
S1P2S1P3 double-null cells (Fig.
5A), indicating negligible contributions of either S1P2 or S1P3 to the
adenylyl cyclase inhibitory actions of S1P. The inhibitory curve
obtained with S1P3-null mice was slightly shifted
rightward, as observed previously (9). Next, we examined the effects of
S1P on the basal cAMP levels in PTX-treated and PTX-untreated
cells (Fig. 5B). S1P did not affect the basal cAMP
levels in PTX-untreated wild-type cells, as observed previously (9);
however, it significantly increased the basal cAMP levels in
PTX-treated cells (Fig. 5B, upper left panel). In
contrast, S1P significantly decreased the basal cAMP levels in
untreated S1P2S1P3 double-null cells, whereas
it did not affect those in PTX-treated double-null cells (Fig.
5B, lower right panel). Both of the S1P actions
(stimulatory and inhibitory) on either S1P2-null or
S1P3-null cells seemed to be in between those on wild-type
and double-null cells (Fig. 5B, upper right and
lower left panels).
S1P-induced Rho Activation in MEF Cells--
S1P-induced
activation of Rho or Rac was examined using activated Rho or Rac
pull-down assays (Fig. 6). S1P activated
Rho in wild-type and S1P3-null cells in a similar fashion
(Fig. 6A), as observed previously (9). In contrast, S1P
activated Rho to a much lesser extent in S1P2-null cells.
Interestingly, S1P failed to activate Rho in double-null cells (Fig.
6A). LPA activated Rho similarly in all of the mutant MEF
cells (Fig. 6B), indicating that the lipid-receptor-Rho
coupling was not generally impaired in the mutant MEF cells. These
results indicate both major roles of S1P2 and minor roles
of S1P3 in S1P-induced Rho activation in MEF cells. S1P did
not induce Rac activation in any of the MEF cell types (Fig.
6C).
The existence of multiple S1P receptors with different functions
in native cells underlies a variety of cellular responses elicited by
S1P. Among five cognate mammalian S1P receptor genes, the
expression of s1p1-3 is widespread throughout the
mouse body, whereas that of s1p4 and
s1p5 is more restricted (9, 12, 15, 16). It has been
shown that many primary cell types such as MEFs (8, 9), atrial and
ventricular myocytes (17), aortic smooth muscle cells (18), aortic
endothelial cells (19, 20), and umbilical vein endothelial cells (20)
express s1p1-3. Thus, it is likely that these three
receptors are the primary in vivo targets of this
serum-borne bioactive lipid in the cardiovascular system. In fact,
S1P1-null mice were lethal between embryonic days 12.5 and
14.5 because of incomplete vascular maturation (8). Also, a single
point mutation in the s1p2-related mil
gene in zebrafish leads to abnormal heart development (21). In
contrast, S1P3-null mice appear to be grossly normal (9).
These results indicate that, despite similar expression patterns in
mice, each receptor can have distinct roles.
The s1p2 gene was first isolated as a putative G
protein-coupled receptor orphan from rat cardiovascular and nervous
systems (22, 23). In the nervous system, s1p2 is
preferentially expressed in young differentiating neuronal cell bodies
and axons, and its temporal expression pattern is correlated with
neuronal differentiation, including axon outgrowth (24). Moreover,
experiments using antisense probes indicated that S1P2 is
involved in neurite outgrowth and cell to cell interactions (25). These
observations imply physiological roles of S1P2 in nervous
system development. To examine these hypothesized functions of
S1P2 in vivo, we generated S1P2-null mice.
Our findings support nonessential roles of S1P2 in normal
mouse development. S1P2-null mice were viable and fertile
and developed normally, even though we observed slightly smaller litter
sizes from homozygous-null mating
(s1p2 In contrast to our findings, analyses of S1P2-null mice in
a recent study by MacLennan et al. (35) suggested more
critical physiological role(s) of S1P2 in mice. The authors
observed that S1P2-null mice occasionally had spontaneous
and sporadic seizures between 3 and 7 weeks of age, accompanied by
ictal-like electroencephalographic abnormalities and hyperexcitable
neocortical pyramidal neurons with apparently normal structure of the
nervous system (35). The seizures in S1P2-null mice often
( The normal viability and fertility of S1P2-null and
S1P3-null mice enabled us to generate
S1P2S1P3 double-null mice. The deletion of both
genes did not affect the expression of the other S1P receptor genes in
the tissues tested (Fig. 1D, right panel).
Double-null mice that survived were also viable and fertile and
developed normally, similar to S1P2-null and
S1P3-null mice. However, the numbers of double-null mice
generated by various kinds of crossbreeding were fewer than expected
(Table II). Most notably, double-null mice from double-null
mating showed vastly reduced perinatal survival, which was not observed
in other genetic crosses (Table II). The double-null matings produced
only 65:21 = 3.1 pups/litter at birth, and only 1.2 pups/litter
survived until weaning ages (n = 21) (Table II).
Such low productivity and survival rates are not solely explainable by
intrinsic defects in double-null pups because significant numbers of
double-null mice could be generated from the other crosses (Table II).
Similarly, the results cannot be solely accounted for by parental
defects because
s1p2 Clear alterations in S1P-induced signal transduction were observed in
mutant MEF cells (summarized in Table
III). The deletion of
s1p2 did not affect S1P-induced PLC activation on
either the s1p3+/+ or
s1p3
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]dCTP and
myo-[2-3H]inositol were purchased from
Perkin-Elmer Life Sciences. S1P and lysophosphatidic acid (LPA;
1-oleoyl-2-hydroxy-sn-glycero-3-phosphate) were
purchased from Avanti Polar Lipids (Alabaster, AL). Pertussis toxin
(PTX) and Fura 2/AM were purchased from Calbiochem and Wako Pure
Chemical Industries (Osaka, Japan). Rhotekin Rho-binding domain- and
PAK1 p21-binding domain-conjugated agarose beads were both purchased
from Upstate Biotechnology, Inc. (Lake Placid, NY). The pMC1DT-3 vector
(10) was a kind gift from Dr. Takeshi Yagi (National Institute for
Physiological Sciences, Okazaki, Japan). The pFlox vector (11) and R1
embryonic stem cells were generous gifts from Dr. Jamey D. Marth
(University of California at San Diego). Trizol and all cell culture
reagents were purchased from Invitrogen. Forskolin,
3-isobutyl-1-methylxanthine, and other reagents were purchased from
Sigma, unless otherwise noted. Mice (C57BL/6NCrlBr) were purchased from
Charles River Laboratories (Wilmington, MA).
clone from a 129/SvJ mouse genomic DNA
library (Stratagene, La Jolla, CA) was described previously (12). The
1.7-kb PGKneo gene (a NheI/BamHI
fragment of the pFlox vector (11)), the 6.5-kb long arm (a
BglII/XhoI fragment upstream of the open reading
frame (ORF)), and the 1.0-kb short arm (a NotI/XbaI fragment downstream of the ORF) were
subcloned successively into the pBluescript SK(+) vector (Stratagene).
Then, the NotI/XhoI fragment of the vector was
cloned into the NotI/XhoI sites of the pMC1DT-3
vectors, producing the s1p2 targeting vector used in
this study. The NotI-linearized targeting construct was
electroporated into R1 embryonic stem cells using Gene-Pulser II
(Bio-Rad). The targeting was completed by homologous recombination
under G418 (200 µg/ml) positive selection and diphtheria toxin A
subunit-catalyzed negative selection, which produced a recombinant
knockout allele in embryonic stem cells. A hemizygous embryonic
stem clone was injected into C57BL/6N blastocysts to produce chimeric
male mice, which were then crossed with C57BL/6N females to obtain
agouti s1p2-heterozygous pups. All mice
analyzed were obtained from intercrosses between their progenies,
s1p3-heterozygous or -homozygous (9), and C57BL/6N mice.
) males and females
(N3-N5) were bred to obtain all three genotypes, wild-type
(s1p2+/+), heterozygous
(s1p2+/
), and homozygous
(s1p2
/
), within the litters. For
S1P2S1P3 double-null analysis,
s1p2+/
s1p3
/
males and females on mixed backgrounds of 129/SvJ and C57BL/6N were bred to obtain three genotypes,
s1p2+/+s1p3
/
,
s1p2+/
s1p3
/
,
and
s1p2
/
s1p3
/
,
within the litters. In both analyses, these littermates were compared
at three developmental stages (10 days and 4 and 8 weeks) as described
previously (9). The mice were anesthetized with Nembutal sodium
solution (0.75 mg/g of body weight; Abbott). Anesthetized mice were
perfused through the heart with 0.9% NaCl, followed by 4%
paraformaldehyde in phosphate-buffered saline. Each tissue (except
brain) was dissected out, post-fixed overnight in 4% paraformaldehyde in phosphate-buffered saline at 4 °C, and processed for paraffin embedding. Five-µm sections were cut, processed, and stained with hematoxylin and eosin according to standard protocols. For brain analysis, whole brain was dissected out, post-fixed as described above,
cryoprotected in 30% sucrose, and sectioned on a cryostat. Twenty-µm
sections were cut and then stained with cresyl violet according to
standard protocols.
2 test (in
tables), and a difference of p < 0.01 was considered to be statistically significant.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
or
s1p2
/
) were established. Mice
genotypes were confirmed by Southern blot (Fig. 1B,
right panel) or PCR (Fig. 1C) analysis using tail genomic DNA. The complete absence of s1p2
transcripts in s1p2
/
mice was
confirmed by Northern blot analysis of adult tissues in which
s1p2 is normally expressed at high levels (9):
heart, brain, lung, and spleen (Fig. 1D, left
panel). Moderate levels of s1p2 expression were
observed in s1p2+/
tissues (Fig.
1D, left panel). In those tissues, several other S1P receptor genes (s1p1 and
s1p3-5) and an LPA receptor gene
(lpa1) were also expressed. There were no
significant changes in the expression levels of those genes related to
s1p2 deficiency.

View larger version (53K):
[in a new window]
Fig. 1.
Generation of S1P2-null and
S1P2S1P3 double-null mice. A,
s1p2 gene targeting. The structures of the wild-type
(WT) allele, targeting construct, and recombinant
(Rec; or knockout (KO)) allele are shown. The
s1p2 ORF was replaced with the neomycin-resistance
gene (neo) driven by the phosphoglycerate kinase
(PGK) promoter. The Southern blot probes (Probes
A and B) and the sizes of the restriction enzyme
(EcoRI) fragments detected with those probes are indicated.
Approximate positions of PCR primers used for genotyping are also
shown. DTA, diphtheria toxin A. B, Southern blot
analysis of EcoRI-digested genomic DNA from properly
targeted R1 embryonic stem (ES) cell clones and mutants
generated by crossing s1p2-heterozygous
(Het) mice. C, PCR genotyping for
s1p2 (PCR product sizes of 270 and 130 bp,
respectively). D, Northern blot analysis of RNAs from heart,
brain, lung, and spleen isolated from adult male wild-type,
s1p2-heterozygous, and
s1p2-knockout littermates on an
s1p3-wild-type (left panel) or
s1p3-knockout (right panel) background.
The probes used are indicated. Ribosomal 28 S RNA stained with ethidium
bromide is shown as a loading control.
males × wild-type females (6.5 versus 8.6 pups/litter). The average size from s1p2+/
males × s1p2
/
females (6.7 pups/litter) was
smaller than that from s1p2+/
males × wild-type females (8.6 pups/litter) or from
s1p2
/
males × s1p2+/
females (8.1 pups/litter)
(Table I), suggesting possible defects in
s1p2
/
females, but not in
s1p2
/
males.
Inheritance of the s1p2 mutant allele
littermates in gross
appearance, general behavior, overall health, and longevity (through at
least 20 months). There were no significant differences in body weights
among s1p2 genotypes in littermates at 4 or 8 weeks
of age in each sex (data not shown). Routine histology was performed in
major tissues (brain, heart, lung, thymus, liver, kidney, spleen,
adipose tissues, skin, muscle, stomach, intestine, uterus, and testis)
from mice at 10 days and 4 and 8 weeks of age and revealed no obvious
differences among s1p2 genotypes in littermates of
either sex (data not shown). Also, routine hematology, including
erythrocyte, leukocyte, and platelet counts; neutrophil, lymphocyte,
monocyte, and eosinophil proportions; glucose, cholesterol, and
triglyceride serum levels; and lipase activity (9), failed to detect
any abnormality or difference in S1P2-null
versus wild-type mice (data not shown).
s1p3+/
double-heterozygous mice were produced from any of the following crosses: s1p2
/
males × s1p3
/
females,
s1p3
/
males × s1p2
/
females,
s1p2
/
s1p3
/
males × wild-type females, and wild-type males × s1p2
/
s1p3
/
females, which gave averages of 5.8-7.0 pups/litter (Table
II). Next,
s1p2+/
s1p3+/
mice were bred to produce 12 s1p2
/
s1p3
/
mice (eight males and four females). The breeding produced several s1p2+/
s1p3
/
or
s1p2
/
s1p3+/
mice, which were also used to produce double-null mice (Table II). The
most striking phenotype of the double-null mice was revealed in the
vastly reduced number of progeny obtained by crossing double-null mice,
far less than expected based on the mendelian frequency (Table II).
Inheritance of the s1p2 and s1p3 mutant alleles
s1p3
/
intercrosses were analyzed with their S1P3-null littermates
as controls because our previous studies did not reveal any major
phenotypic abnormality in S1P3-null mice (9). The complete
absence of s1p2 and s1p3 transcripts in double-null mice was confirmed by Northern blot analysis
of RNA samples from heart, brain, lung, and spleen (Fig. 1D,
right panel). There was no obvious compensatory gene
expression of other S1P receptors (Fig. 1D, right
panel). Double-null mice did not differ from their
S1P3-null littermates in gross appearance, general
behavior, overall health, body weight, and longevity (through at least
16 months) (data not shown). Routine histology and hematology did not
reveal any gross differences related to S1P2 deficiency on
the s1p3
/
background (data not
shown). However, double-null pups generated by double-null mating were
lost perinatally at high frequency. Among 65 neonates (including
carcasses) produced from 21 pregnancies, 39 neonates were found dead
within 1 week after birth (most died within 24 h); the remaining
26 neonates survived to adulthood. Maternal negligence of pups was
observed in most of the 13 pregnancies with no neonatal survivors, a
phenomenon rarely observed in the other crosses. Among eight
pregnancies that had survivors, one pregnancy had six survivors, two
had four each, three had three each, one had two, and one had one
(total of 26 mice). Unexpectedly, the neonatal survivors grew up
normally and did not show any obvious abnormality with maturation.

View larger version (55K):
[in a new window]
Fig. 2.
Expression of S1P receptor genes in
wild-type, S1P2-null, S1P3-null, and
S1P2S1P3 double-null MEF cells. MEF cell
RNAs prepared from wild-type (WT) and knockout
(KO) embryonic day 14 embryos were analyzed by Northern blot
analysis. Tissue RNA isolated from an adult C57BL/6N female was used as
a positive control (heart RNA for s1p1-3,
lung RNA for s1p4, and brain RNA for
s1p5). As loading control, ribosomal 28 S RNA was
stained with ethidium bromide.

View larger version (30K):
[in a new window]
Fig. 3.
S1P-induced inositol phosphate production in
MEF cells. MEF cells (wild-type (WT) and each mutant)
prelabeled with [3H]inositol were stimulated with various
concentrations of S1P or LPA for 20 min, and the radioactivity in the
inositol phosphate fraction of the cell extract was determined. The
activity is expressed as a percent response compared with 10 µM LPA as 100%. The responses to LPA were comparable in
all of the MEF cells (4.3-6.0-fold induction above basal levels). Data
shown are the means ± S.E. of triplicate samples. Error
bars are not shown when the bars are smaller than the size of the
data points. KO, knockout.

View larger version (15K):
[in a new window]
Fig. 4.
S1P-induced intracellular calcium
mobilization in MEF cells. MEF cells (wild-type (WT)
and each mutant) were loaded with Fura 2/AM and stimulated successively
with 10 µM S1P, 10 µM LPA, and 1 mM ATP. The increases in nanomolar intracellular
Ca2+ ([Ca2+]i) from
the basal levels (
150 nM) are shown. Data are
representative of three independent experiments. KO,
knockout.

View larger version (36K):
[in a new window]
Fig. 5.
S1P-induced modulation of adenylyl cyclase
activity in MEF cells. Intracellular cAMP content after 20-min
stimulation of the cells was measured by enzyme immunoassay.
A, S1P concentration-dependent inhibition of 1 µM forskolin-induced cAMP accumulation in the presence of
0.5 mM 3-isobutyl-1-methylxanthine. Forskolin-induced cAMP
accumulation is expressed as 100%. B, MEF cells pretreated
without and with PTX (100 ng/ml, 24 h) and then stimulated for 20 min with 1 µM S1P in the presence of 0.5 mM
3-isobutyl-1-methylxanthine. The effects of S1P were significant (*,
p < 0.01). In all panels, data shown are the
means ± S.E. of triplicate samples. Error bars are not
shown when the bars are smaller than the size of the data
points. WT, wild-type; KO, knockout.

View larger version (55K):
[in a new window]
Fig. 6.
S1P-induced Rho activation in MEF cells.
Wild-type (WT) and knockout (KO) MEF cells were
stimulated with 1 µM S1P (A and C)
or LPA (B) for 3 min, and the cell lysate was used for
affinity precipitation with Rhotekin Rho-binding domain- and PAK1
p21-binding domain-conjugated agarose beads to pull down activated
forms of Rho and Rac, respectively. The lysate was also used to
determine total Rho or Rac levels. Samples were separated on 15%
SDS-polyacrylamide gels and analyzed by Western blot analysis using
anti-RhoA or anti-Rac1 antibody. Data are representative of three
independent experiments.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
× s1p2
/
) (Table I), as seen with
S1P3-null mating (9). These data suggest a potential role
of S1P2 and S1P3 in reproduction, as implied by
expression of s1p2 and s1p3 in
gonadal tissues (9), the abundant existence of S1P in testis (26), and
prevention of oocyte apoptosis by S1P (27). However, functional and
histological analyses revealed no obvious phenotypic abnormality in
S1P2-null reproductive and other organs examined. Previous
studies on mammalian receptor overexpression systems showed that
S1P2 resembles S1P3 in G protein coupling and
signal transduction (28-32), even though a distinct role in Rac
activation was recently reported in Chinese hamster ovary cells (33)
and vascular smooth muscle cells (34). Our previous work demonstrated
the possible compensatory expression of s1p2 in
S1P3-null mouse brain and heart (9), which might explain
the lack of major phenotypes in S1P3-null mice. However, there was no such compensatory expression of s1p genes in
S1P2-null mice in this study (Fig. 1D,
left panel).
14%) resulted in death (35). We did not observe seizures or
epileptic death in our S1P2-null mice during those ages,
and the basis for the discrepancy remains unclear. In our studies,
almost all the pups (irrespective of genotypes) that survived through
the first week after birth survived to adulthood. One possible
explanation is a difference in the genetic background of the mutants:
MacLennan et al. analyzed their mice on a C57BL/6 (albino)
background (N2-N4), whereas we analyzed our mice on a C57BL/6N
background (N3-N5).
/
s1p3
/
males × wild-type females as well as wild-type males × s1p2
/
s1p3
/
females could produce and nurture significant numbers of pups (6.7 and
5.8 pups/litter, respectively). Thus, these data support an
interpretation in which combined S1P2 and S1P3
receptor signaling has roles in prenatal development as well as
parent-offspring interactions such as lactation and suckling. This
latter interaction is reminiscent of the phenotype observed in mutants
of the LPA1 receptor (36), which is notable in view of the
close evolutionary link between LPA and S1P receptors (4).
/
background (Fig. 3), which
supports our previous finding that S1P2 is not involved in
S1P-induced PLC activation in MEF cells (9). The deletion of
s1p3, but not s1p2, diminished
S1P-induced intracellular calcium mobilization (Fig. 4), indicating a
primary role of S1P3 in that response. The deletion of
s1p2 also did not affect S1P-induced inhibition of
forskolin-activated cAMP accumulation (Fig. 5A). A slight
decrease in sensitivity to S1P was observed in S1P3-null
MEF cells (Fig. 5A) (9), but not in
S1P2S1P3 double-null MEF cells (Fig.
5A). In addition, S1P decreased basal cAMP production in a
PTX-sensitive manner in S1P2S1P3 double-null
MEFs. Because expression of s1p4 and
s1p5 was not detectable in MEF cells (Fig. 2), these
observations suggest a primary role of S1P1 in S1P-induced adenylyl cyclase inhibition.
S1P cellular signaling properties in mutant MEF cells
and
stand for
minimal and no responses, respectively. [Ca2+]i,
intracellular [Ca2+]; AC, adenylyl cyclase; KO, knockout.
Previous studies using mammalian receptor overexpression systems indicated that S1P2 and/or S1P3 can mediate S1P-induced cAMP accumulation in the absence of forskolin, an adenylyl cyclase activator (Refs. 30 and 37; reviewed in Refs. 2 and 5). Using MEF cells, we have clearly shown that basal cAMP levels are regulated (or balanced) by two opposing S1P receptor-mediated signaling pathways. One is the PTX-sensitive, Gi/o-mediated adenylyl cyclase inhibition through S1P1 described above. In addition, we observed PTX-insensitive adenylyl cyclase activation, which was observed when Gi/o inhibition was blocked with PTX and which appeared to be mediated through S1P2 and S1P3 because it was lost in the double-null cells. These effects may be mediated via coupling to Gs or effects of elevated intracellular calcium or other adenylyl cyclase regulators such as protein kinase C (38, 39). Because s1p3 overexpression enhances S1P inhibition of forskolin-activated cAMP accumulation in MEFs (9), the effect of S1P3 on adenylyl cyclase activity may vary depending on the receptor expression levels or the activation state of adenylyl cyclase.
We previously showed that S1P induces Rho activation in wild-type MEF cells and that S1P3 deletion does not affect this response (9). Because this S1P activation in wild-type MEFs is PTX-insensitive (9) and the S1P1 receptor has been shown to act only through PTX-sensitive G proteins, a prominent role of S1P2 in S1P-induced Rho activation in MEF cells was postulated (9). In this study, we demonstrated that the deletion of s1p2 resulted in a significant decrease in S1P-induced Rho activation, whereas responses to LPA remained intact (Fig. 6, A and B). Surprisingly, the S1P response was not fully lost in S1P2-null MEF cells, although it was totally abolished in double-null MEF cells. The observation that the s1p3 deletion did not significantly decrease S1P-induced Rho activation (Fig. 6) (9) may reflect the lack of sensitivity in quantifying small decreases in the amount of active Rho. However, it may also be argued that S1P2 is the receptor that predominantly couples to the G12/13/Rho pathway; only in its absence is the ability of S1P3 to serve a redundant role in this fundamental response observed. S1P did not induce Rac activation in MEF cells, which contrasts with previous results by Liu et al. (8).
In this and previous (9) studies on single mutant mice, we demonstrated
no requirement of S1P2 or S1P3 for normal
development or physiological function of mice. Considering the
universal expression of s1p1-3 throughout the mouse
body and the profound phenotypes found in S1P1-null mice
(e.g. hemorrhage and embryonic lethality), S1P-induced
activation of PTX-sensitive G proteins (Gi/o) through S1P1 rather than that of PTX-insensitive G proteins
(Gq and G12/13) through S1P2 or
S1P3 seems to be essential for mouse development. Through
Gi/o proteins, S1P has been shown to activate
mitogen-activated protein kinase and phosphoinositide 3-kinase (29, 40,
41), both of which are well characterized for their involvement in cell
proliferation and survival, respectively. The defects in such
Gi/o downstream signaling could be relevant to the vascular phenotypes observed in S1P1-null mice. However, S1P has
also been shown to be a potent inducer of cell differentiation and
migration responses, in which Rho activation by Gq or
G12/13 could play a major role (42, 43). In
S1P2S1P3 double-null MEF cells, there was a
complete loss of S1P-induced Rho activation, clearly showing
non-redundant S1P signaling properties. In addition, greatly decreased
litter size and marked perinatal lethality were observed in double-null
mice. New phenotypes may be unmasked in these mutants when challenged
by injury, disease, or other stressors.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Grace Kennedy, Marisa Fontanoz, and Carol Akita for technical assistance.
| |
FOOTNOTES |
|---|
* This work was supported by an unrestricted gift from Merck Research Laboratories (to J. C.); National Institute of Mental Health Grant R01 MH51699 (to J. C.); a grant from the Mitsubishi Pharma Research Foundation (to I. I.); National Science Foundation Grant 00747776 (to B. F.); National Institutes of Health Grants GM36927 and HL28143 (to S. K. and J. H. B.), Neuroplasticity of Aging Training Grant 5T32AG00216 (to M. A. K.), and NIGMS Pharmacology Training Grant 2T32GM07752 (to A. H. Y.); and a grant from the National Institute of Neuroscience, NCNP, Japan (to Dr. Hideo Kimura).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Merck Research
Laboratories, San Diego, 3535 General Atomics Ct., San Diego, CA 92121. Tel.: 858-202-5232; Fax: 858-202-5813; E-mail:
jerold_chun@merck.com.
Published, JBC Papers in Press, May 2, 2002, DOI 10.1074/jbc.M200137200
2 J. J. A. Contos, I. Ishii, N. Fukushima, M. A. Kingsbury, X. Ye, and J. Chun, submitted for publication.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: S1P, sphingosine 1-phosphate; MEF, mouse embryonic fibroblast; PLC, phospholipase C; LPA, lysophosphatidic acid; PTX, pertussis toxin; PAK, p21-activated kinase; ORF, open reading frame; BSA, bovine serum albumin.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Spiegel, S., and Milstien, S. (2000) Biochim. Biophys. Acta 1484, 107-116[Medline] [Order article via Infotrieve] |
| 2. | Pyne, S., and Pyne, N. (2000) Pharmacol. Ther. 88, 115-131[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Pyne, S., and Pyne, N. J. (2000) Biochem. J. 349, 385-402[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Fukushima, N., Ishii, I., Contos, J. J., Weiner, J. A., and Chun, J. (2001) Annu. Rev. Pharmacol. Toxicol. 41, 507-534[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Takuwa, Y., Okamoto, H., Takuwa, N., Gonda, K., Sugimoto, N., and Sakurada, S. (2001) Mol. Cell. Endocrinol. 177, 3-11[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Tigyi, G.
(2001)
Mol. Pharmacol.
60,
1161-1164 |
| 7. |
Hla, T.,
Lee, M. J.,
Ancellin, N.,
Paik, J. H.,
and Kluk, M. J.
(2001)
Science
294,
1875-1878 |
| 8. | Liu, Y., Wada, R., Yamashita, T., Mi, Y., Deng, C. X., Hobson, J. P., Rosenfeldt, H. M., Nava, V. E., Chae, S. S., Lee, M. J., Liu, C. H., Hla, T., Spiegel, S., and Proia, R. L. (2000) J. Clin. Invest. 106, 951-961[Medline] [Order article via Infotrieve] |
| 9. |
Ishii, I.,
Friedman, B., Ye, X.,
Kawamura, S.,
McGiffert, C.,
Contos, J. J.,
Kingsbury, M. A.,
Zhang, G.,
Brown, J. H.,
and Chun, J.
(2001)
J. Biol. Chem.
276,
33697-33704 |
| 10. | Yagi, T., Nada, S., Watanabe, N., Tamemoto, H., Kohmura, N., Ikawa, Y., and Aizawa, S. (1993) Anal. Biochem. 214, 77-86[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Marth, J. D. (1996) J. Clin. Invest. 97, 1999-2002[Medline] [Order article via Infotrieve] |
| 12. | Zhang, G., Contos, J. J., Weiner, J. A., Fukushima, N., and Chun, J. (1999) Gene (Amst.) 227, 89-99[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Ishii, I.,
Contos, J. J.,
Fukushima, N.,
and Chun, J.
(2000)
Mol. Pharmacol.
58,
895-902 |
| 14. |
Ishii, I.,
Izumi, T.,
Tsukamoto, H.,
Umeyama, H., Ui, M.,
and Shimizu, T.
(1997)
J. Biol. Chem.
272,
7846-7854 |
| 15. | Graler, M. H., Bernhardt, G., and Lipp, M. (1998) Genomics 53, 164-169[CrossRef][Medline] [Order article via Infotrieve] |
| 16. |
Im, D. S.,
Heise, C. E.,
Ancellin, N.,
O'Dowd, B. F.,
Shei, G. J.,
Heavens, R. P.,
Rigby, M. R.,
Hla, T.,
Mandala, S.,
McAllister, G.,
George, S. R.,
and Lynch, K. R.
(2000)
J. Biol. Chem.
275,
14281-14286 |
| 17. | Liliom, K., Sun, G., Bunemann, M., Virag, T., Nusser, N., Baker, D. L., Wang, D. A., Fabian, M. J., Brandts, B., Bender, K., Eickel, A., Malik, K. U., Miller, D. D., Desiderio, D. M., Tigyi, G., and Pott, L. (2001) Biochem. J. 355, 189-197[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Tamama, K., Kon, J., Sato, K., Tomura, H., Kuwabara, A., Kimura, T., Kanda, T., Ohta, H., Ui, M., Kobayashi, I., and Okajima, F. (2001) Biochem. J. 353, 139-146[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Kimura, T., Watanabe, T., Sato, K., Kon, J., Tomura, H., Tamama, K., Kuwabara, A., Kanda, T., Kobayashi, I., Ohta, H., Ui, M., and Okajima, F. (2000) Biochem. J. 1, 71-76 |
| 20. |
Wang, F.,
Van Brocklyn, J. R.,
Hobson, J. P.,
Movafagh, S.,
Zukowska-Grojec, Z.,
Milstien, S.,
and Spiegel, S.
(1999)
J. Biol. Chem.
274,
35343-35350 |
| 21. | Kupperman, E., An, S., Osborne, N., Waldron, S., and Stainier, D. Y. (2000) Nature 406, 192-195[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Okazaki, H., Ishizaka, N., Sakurai, T., Kurokawa, K., Goto, K., Kumada, M., and Takuwa, Y. (1993) Biochem. Biophys. Res. Commun. 190, 1104-1109[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | MacLennan, A. J., Browe, C. S., Gaskin, A. A., Lado, D. C., and Shaw, G. (1994) Mol. Cell. Neurosci. 5, 201-209[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Maclennan, A. J., Marks, L., Gaskin, A. A., and Lee, N. (1997) Neuroscience 79, 217-224[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | MacLennan, A. J., Devlin, B. K., Marks, L., Gaskin, A. A., Neitzel, K. L., and Lee, N. (2000) Dev. Neurosci. 22, 283-295[CrossRef][Medline] [Order article via Infotrieve] |
| 26. |
Yatomi, Y.,
Igarashi, Y.,
Yang, L.,
Hisano, N., Qi, R.,
Asazuma, N.,
Satoh, K.,
Ozaki, Y.,
and Kume, S.
(1997)
J. Biochem. (Tokyo)
121,
969-973 |
| 27. | Morita, Y., Perez, G. I., Paris, F., Miranda, S. R., Ehleiter, D., Haimovitz-Friedman, A., Fuks, Z., Xie, Z., Reed, J. C., Schuchman, E. H., Kolesnick, R. N., and Tilly, J. L. (2000) Nat. Med. 6, 1109-1114[CrossRef][Medline] [Order article via Infotrieve] |
| 28. |
Windh, R. T.,
Lee, M. J.,
Hla, T., An, S.,
Barr, A. J.,
and Manning, D. R.
(1999)
J. Biol. Chem.
274,
27351-27358 |
| 29. |
An, S.,
Zheng, Y.,
and Bleu, T.
(2000)
J. Biol. Chem.
275,
288-296 |
| 30. |
Kon, J.,
Sato, K.,
Watanabe, T.,
Tomura, H.,
Kuwabara, A.,
Kimura, T.,
Tamama, K.,
Ishizuka, T.,
Murata, N.,
Kanda, T.,
Kobayashi, I.,
Ohta, H., Ui, M.,
and Okajima, F.
(1999)
J. Biol. Chem.
274,
23940-23947 |
| 31. |
Van Brocklyn, J. R., Tu, Z.,
Edsall, L. C.,
Schmidt, R. R.,
and Spiegel, S.
(1999)
J. Biol. Chem.
274,
4626-4632 |
| 32. |
Ancellin, N.,
and Hla, T.
(1999)
J. Biol. Chem.
274,
18997-19002 |
| 33. |
Okamoto, H.,
Takuwa, N.,
Yokomizo, T.,
Sugimoto, N.,
Sakurada, S.,
Shigematsu, H.,
and Takuwa, Y.
(2000)
Mol. Cell. Biol.
20,
9247-9261 |
| 34. |
Ryu, Y.,
Takuwa, N.,
Sugimoto, N.,
Sakurada, S.,
Usui, S.,
Okamoto, H.,
Matsui, O.,
and Takuwa, Y.
(2002)
Circ. Res.
90,
325-332 |
| 35. | MacLennan, A. J., Carney, P. R., Zhu, W. J., Chaves, A. H., Garcia, J., Grimes, J. R., Anderson, K. J., Roper, S. N., and Lee, N. (2001) Eur. J. Neurosci. 14, 203-209[CrossRef][Medline] [Order article via Infotrieve] |
| 36. |
Contos, J. J.,
Fukushima, N.,
Weiner, J. A.,
Kaushal, D.,
and Chun, J.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
13384-13389 |
| 37. | Gonda, K., Okamoto, H., Takuwa, N., Yatomi, Y., Okazaki, H., Sakurai, T., Kimura, S., Sillard, R., Harii, K., and Takuwa, Y. (1999) Biochem. J. 337, 67-75 |
| 38. |
Taussig, R.,
and Gilman, A. G.
(1995)
J. Biol. Chem.
270,
1-4 |
| 39. | Hanoune, J., and Defer, N. (2001) Annu. Rev. Pharmacol. Toxicol. 41, 145-174[CrossRef][Medline] [Order article via Infotrieve] |
| 40. | Rakhit, S., Conway, A. M., Tate, R., Bower, T., Pyne, N. J., and Pyne, S. (1999) Biochem. J. 338, 643-649 |
| 41. |
Banno, Y.,
Takuwa, Y.,
Akao, Y.,
Okamoto, H.,
Osawa, Y.,
Naganawa, T.,
Nakashima, S.,
Suh, P. G.,
and Nozawa, Y.
(2001)
J. Biol. Chem.
276,
35622-35628 |
| 42. | Lee, M. J., Thangada, S., Claffey, K. P., Ancellin, N., Liu, C. H., Kluk, M., Volpi, M., Sha'afi, R. I., and Hla, T. (1999) Cell 99, 301-312[CrossRef][Medline] [Order article via Infotrieve] |
| 43. |
Paik, J. H.,
Chae, S.,
Lee, M. J.,
Thangada, S.,
and Hla, T.
(2001)
J. Biol. Chem.
276,
11830-11837 |
| 44. | Yang, A. H., Ishii, I., and Chun, J. (2002) Biochim. Biophys. Acta, in press |